youtube_live
Q3 2026 earnings • released • EPS miss -23.69% • Revenue beat +4.73%
See resultschevron_right
INSM:NASDAQ
Insmed Inc
$109.31
arrow_downward
-2.90%(-3.27) 1D
$109.31
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INSM...
Open
$112.68
High
$113.05
Low
$109.22
Mkt. cap
23.98B
Avg. vol.
3.30M
Volume
0.00
52-wk high
$212.75
52-wk low
$90.39
EPS
-$2.82
Beta
0.83
Shares outstanding
219.38M
No. of employees
2K
Open
$112.68
High
$113.05
Low
$109.22
Mkt. cap
23.98B
Avg. vol.
3.30M
Volume
0.00
52-wk high
$212.75
52-wk low
$90.39
EPS
-$2.82
Beta
0.83
Shares outstanding
219.38M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
16 hours ago
Guggenheim cuts Insmed stock price target on model changes to $201
Yahoo Finance
·
3 days ago
Insmed (INSM) Begins BRINSUPRI Sales In Japan
About Insmed Inc
CEOWilliam H. Lewis
Employees1.66K
Founded1988
HeadquartersBridgewater, New Jersey, United States
SectorBiotechnology
Websiteinsmed.com
Analyst ratings
Based on 22 analysts giving stock ratings to INSM in the past 3 months
Strong buy
Buy
21
Hold
1
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for INSM in the last 3 months.
Highest
Current $109.31
$243.00 (+122.30%)
Average
$194.60 (+78.03%)
Lowest
$154.00 (+40.88%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst Leerink Partners | Buy | Maintained | $198.00 | +81.1% | 11/02/2026 |
Vamil Divan Guggenheim | Buy | Reiterated | $201.00 | +83.9% | 11/01/2026 |
Eliana Merle Barclays | Buy | Maintained | $207.00 | +89.4% | 11/02/2026 |
Conor MacKay BMO Capital | Buy | Maintained | $192.00 | +75.6% | 11/02/2026 |
Maxwell Skor Morgan Stanley | Buy | Reiterated | $213.00 | +94.9% | 10/30/2026 |
Andrea Newkirk Goldman Sachs | Buy | Maintained | $194.00 | +77.5% | 10/30/2026 |
Ashwani Verma UBS | Buy | Maintained | $172.00 | +57.4% | 10/30/2026 |
Leonid Timashev RBC Capital | Buy | Reiterated | $195.00 | +78.4% | 10/29/2026 |
Adam Walsh Roth MKM | Buy | Maintained | $204.00 | +86.6% | 10/29/2026 |
Graig Suvannavejh Mizuho Securities | Buy | Maintained | $154.00 | +40.9% | 10/29/2026 |
Andrew Fein H.C. Wainwright | Buy | Reiterated | $220.00 | +101.3% | 10/27/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $173.00 | +58.3% | 10/20/2026 |
Benjamin Burnett Wells Fargo | Buy | Reiterated | $169.00 | +54.6% | 10/13/2026 |
Jason Zemansky Bank of America Securities | Buy | Reiterated | $207.00 | +89.4% | 10/12/2026 |
Andy Chen Wolfe Research | Hold | Downgraded | - | - | 10/12/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | $175.00 | +60.1% | 09/28/2026 |
Danielle Brill Truist Financial | Buy | Reiterated | $195.00 | +78.4% | 08/10/2026 |
Olivia Brayer Cantor Fitzgerald | Buy | Maintained | $235.00 | +115% | 08/06/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $170.00 | +55.5% | 08/07/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $243.00 | +122.3% | 08/06/2026 |
Faisal Khurshid Jefferies | Buy | Maintained | $175.00 | +60.1% | 08/06/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 08/06/2026 |
Evan Seigerman BMO Capital | Buy | Initiated | $192.00 | +75.6% | 07/21/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $192.00 | +75.6% | 07/20/2026 |
Stephen Willey Stifel Nicolaus | Buy | Maintained | $200.00 | +83% | 07/17/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $175.00 | +60.1% | 06/23/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | $243.00 | +122.3% | 05/20/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $180.00 | +64.7% | 05/20/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $162.00 | +48.2% | 05/15/2026 |
Unknown Analyst Raymond James | Buy | Initiated | $200.00 | +83% | 04/09/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.46 / -$0.37
-23.69%miss
arrow_downward
Revenue / Est. (USD)
524.43M / 500.73M
+4.73%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 263.84M | 305.96M | 425.49M | 524.43M |
Cost of goods sold | 44.22M | 47.42M | 67.21M | 78.22M |
Cost of revenue | 44.22M | 47.42M | 67.21M | 78.22M |
Research and development expenses | 254.91M | 209.48M | 210.03M | 269.96M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 212.48M | 247.26M | 247.47M | 253.03M |
Operating expense | 469.33M | 458.82M | 459.58M | 528.04M |
Total operating expenses | 513.55M | 506.24M | 526.79M | 606.26M |
Operating income | -249.71M | -200.28M | -101.31M | -81.83M |
Other non operating income | -1.82M | -736.00K | -531.00K | 1.06M |
EBT including unusual items | -326.93M | -162.10M | -11.37M | -97.65M |
EBT excluding unusual items | -256.89M | -209.06M | -111.13M | -90.11M |
Income tax expense | 1.55M | 1.46M | 1.87M | 2.67M |
Effective tax rate | -0.47% | -0.90% | -16.43% | -2.73% |
Other operating expenses | - | - | - | - |
Net income | -328.48M | -163.56M | -13.24M | -100.32M |
Net profit margin | -124.50% | -53.46% | -3.11% | -19.13% |
Earnings per share | -1.54 | -0.76 | -0.06 | -0.46 |
Interest and investment income | 15.24M | 12.04M | 10.98M | 11.07M |
Interest expense | -20.60M | -20.08M | -20.27M | -20.41M |
Net interest expenses | -5.36M | -8.04M | -9.29M | -9.34M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -244.68M | -195.80M | -96.58M | -73.97M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events